NuvOx Pharma Announces FDA Acceptance of IND to Initiate Clinical Trial for Vaso-Occlusive Crisis in Sickle Cell Disease

The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves excruciating, debilitating, episodic pain and can contribute to contribute to infection, stroke, multisystem organ [PR.com]
PR.com Press Releases: Medical & Health: Pharmaceuticals News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us